Open Access<p>Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data</p>
Author(s) -
Alexander E Rock,
Jeremy M. Lerner,
Melissa E Badowski
Publication year - 2020
Publication title -
hiv/aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 22
ISSN - 1179-1373
DOI - 10.2147/hiv.s184018
Subject(s) - antiretroviral therapy , reverse transcriptase inhibitor , human immunodeficiency virus (hiv) , integrase , medicine , integrase inhibitor , pharmacology , virology , viral load
The utility of doravirine in the management of HIV-1 infection is approved for use in patients who are antiretroviral-naïve as well as patients who have achieved stable virologic suppression and are interested in replacing their current antiretroviral therapy. The role of doravirine continues to evolve as data emerges on the potential for new combination therapy with the investigational agent, islatravir, as well as a potential strategy to minimize post-marketing safety concerns with recommended first-line agents, such as integrase inhibitors. The goal of this review is to assess recent and emerging data on the non-nucleoside reverse transcriptase inhibitor, doravirine.